Immunovative Therapies, Ltd. recently announced that its New Drug (IND) application was cleared by the US Food and Drug Administration, allowing the company to begin clinical trials of its experimental CryoStim™ cancer vaccine product for the treatment of advanced metastatic solid tumors. The trials will begin in September at the company’s new clinical research subsidiary in Carlsbad CA.
CryoStim is a treatment that combines the experimental AlloStim™ drug with with cryoablation. AlloStim contains living immune cells attached to microbeads designed to stimulate and direct the human immune system to directly kill cancer cells wherever they reside in the body. This technology is based on the idea that the human immune system is capable of seeking out and destroying cancer cells in the human body.
“CryoStim represents a completely novel approach for therapeutic cancer design,” says Michael Har-Noy PhD, CEO and Chief Technical Officer. “Current therapies are not capable of eliminating every last cancer cell in the body and thus tumor recurrence is a common problem. If our experimental therapy is successful it would be possible to not only eliminate every last tumor cell, but also for the immune system to remember the tumor in order to prevent recurrence.”
For more details, visit www.immunocare.net or clinicaltrials.gov: NCT00861107.
[Source: PRWeb]
